In the first quarter of 2024, a total of 29 million transactions were carried out in the Latvian Medicines Verification System (LZVS), which is a 16% increase compared to the same period in 2023. After the final verification, slightly more than 7.4 million medicine packages were supplied to citizens in Latvia, marking a 4% increase from the first quarter of 2023.
In the first half of 2024, a total of 58 million transactions were recorded in the LZVS, representing an 11% increase compared to the same period in 2023. After final verification, approximately 15 million medicine packages reached the residents in the first half of 2024, which is a 4% increase compared to the first half of 2023.
Overall, the performance and operation of the LZVS have been stable during this period. The system processes transactions and generates alerts as required by the operational standards. The Latvian Medicines Verification Organization (LZVO) has no reports of potential counterfeit medicine cases.
As of June 30, 1192 end-users, including pharmacies, hospital pharmacies, wholesalers, and medical institutions, connected to the verification system. The number of end-users of the LZVS has stabilized over the past year. On average, 5 new user accounts are created each month, and 6 accounts are closed for end-users who do not have a valid medicine purchase permit or pharmaceutical activity license.
The number of alerts has significantly decreased over time. Similar to the previous quarter, the proportion of alerts in the second quarter of 2024 is 0.01% of the total number of transactions. This specific indicator demonstrates the stable operation of the LZVS, and it is significantly lower than the average rate of 0.12% in the participating countries of the European system.
